🔗 Share this article

As America continues making historic changes to its vaccine guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccines throughout the pandemic and has focused upon possible fatalities after Covid vaccination in her recent time at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Public health authorities were set to announce radical revisions to the childhood immunization program recently, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of alignment with many the world with no evidence for public health gain. The planned update has been postponed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric shot schedules in the US in order to be more in line with Denmark, a society with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

Dr. Høeg has little discernible background in drug development, oversight or administrative roles, which has been typical for past directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of CBER would “understand legal statutes and the underlying principles of drug development”, said Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who ran CBER have had.”

CDER has an vast portfolio at the agency, the former commissioner emphasized.

“Many people just zeroes in on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and more, and every single one need to be supervised,” Woodcock said. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant administrative component to the job, which manages more than 5,000 employees. “It is a massive management job, if you do it right,” she concluded.

Agency Reaction and Controversial Programs

When asked about inquiries about Høeg’s qualifications and whether this selection represents increased cooperation among FDA leaders on vaccines, a representative stated that the “inquiries are based on incorrect presumptions”.

“Her resume is consistent with the duties of her position,” the spokesperson explained, citing the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed rapid medication authorization process that apparently troubled her predecessors. “By what process are these medications being selected for this voucher program? Who takes the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards laxer oversight of pharmaceuticals, aside from shots.”

Public History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if problematic, past, critics have noted. She authored a research paper using unconfirmed volunteer-provided data to assess the rate of heart inflammation following COVID-19 vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the new administration featured revising regulations for new vaccines and ending “optional” vaccines, she said after the election on a online show. At the FDA, Høeg has according to sources suggested preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an complete ideologue who starts off with her conclusions and tailors the evidence to fit the data in a extremely deceptive, dishonest fashion,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|